Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Akebia Therapeutics, Inc. (AKBA) had Normalized Pre-Tax Income of $0.25M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$62.47M |
|
$0.25M |
|
$9.92M |
|
$52.55M |
|
$48.38M |
|
$14.09M |
|
$-13.84M |
|
$0.25M |
|
|
Normalized Pre-Tax Income |
$0.25M |
$0.25M |
|
$0.25M |
|
$0.25M |
|
$0.25M |
|
$14.09M |
|
$14.40M |
|
262.57M |
|
271.10M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$234.66M |
|
$1.71M |
|
$110.94M |
|
$345.60M |
|
$118.72M |
|
$47.06M |
|
$197.65M |
|
$316.37M |
|
$29.22M |
|
$-29.82M |
|
$29.22M |
|
263.04M |
|
| Cash Flow Statement Financials | |
$8.76M |
|
$0.03M |
|
$76.66M |
|
$53.55M |
|
$139.00M |
|
$85.45M |
|
$4.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.98 |
|
-- |
|
-- |
|
0.62 |
|
1.61 |
|
84.12% |
|
22.55% |
|
22.55% |
|
-- |
|
0.40% |
|
0.40% |
|
$8.79M |
|
-- |
|
-- |
|
-- |
|
0.18 |
|
0.59 |
|
0.86 |
|
104.89 |
|
0.85% |
|
-0.83% |
|
0.07% |
|
0.32% |
|
$0.11 |
|
$0.03 |
|
$0.03 |
|